Multidimensional impact of COPD exacerbations;Impacto multidimensional de las exacerbaciones de la EPOC

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.11, 2010, Pages 12-19

  Soler Cataluña, Juan José ^a   Martínez García, Miguel Ángel ^a   Serra, Pablo Catalán ^a  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

Author keywords

COPD Exacerbation Prognosis Mortality Health related quality of life

Indexed keywords

ADL DISABILITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MEDICAL HISTORY; PHENOTYPIC VARIATION; PROGNOSIS; QUALITY OF LIFE; TREATMENT PLANNING;

ACUTE DISEASE; COMORBIDITY; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 79851492888     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70057-0     Document Type: Article

References (76)

1. Han M.K., Agustí A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
2. Andersson F., Borg S., Jansson S.A., Jonsson A.C., Ericsson A., Prutz C., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002, 96:700-708.
3. Bourbeau J., Ford G., Zackon H., Pinsky N., Lee J., Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007, 30:907-913.
4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
5. Cote C.G., Dordelly L.J., Celli B.R. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007, 131:696-704.
6. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronico obstructive pulmonary disease. Thorax 2005, 60:925-931.
7. Soler-Cataluña J.J., Martínez-García M.A., Sánchez L., Perpiña M., Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009, 103:692-699.
8. Esteban C., Quintana J.M., Aburto M, Moraza J, Egurrola M, España P.P., et al. Predictors of mortality in patients with stable COPD. J Gen Intern Med 2008, 23:1829-1834.
9. Soler-Cataluña J.J., Rodríguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?. COPD 2010, 7:276-284.
10. Tashkin D.P. Frequent exacerbations of chronic obstructive pulmonary disease - a distinct phenotype?. N Engl J Med 2010, 16:1183-1184.
11. Miravitlles M., Guerrero T., Mayordomo C., Sánchez-Agudo L., Nicolau F., Segú J.L. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000, 67:495-501. on behalf of the EOLO group.
12. Hurst J.R., Vestbo J., Anzeto A., Locantore N., Müllerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
13. Soler J.J., Sánchez L., Latorre M., Alamar J., Román P., Perpiñá M. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 2001, 37:375-381.
14. Seemungal T.A.R., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
15. Spencer S., Calverley P.M.A., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702.
16. Dewan N.A., Rafique S., Kanwar B., Satpathy H., Ryschon K., Tillotson G.S., et al. Acute exaerbation of COPD: factors associated with poor outcome. Chest 2000, 117:662-671.
17. García-Aymerich J., Farrero E., Felez M.A., Izquierdo J., Marrades R.M., Antó J.M. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003, 58:100-105.
18. Niewoehner D.E., Lokhnygina Y., Rice K., Kuschner W.G., Sharafkhaneh A., Sarosi G.A., et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007, 131:20-28.
19. BhowmiK A., Seemungal T.A.R., Sapsford R.J., Wedzicha J.A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55:114-120.
20. Patel I.S., Seemungal T.A.R., Wiks M., Lloyd-Owen S.J., Donaldson G.C., Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57:759-764.
21. Burgel P.R., Nesme-Meyer P., Chanez P., Caillaud D., Carré P., Pérez T., et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009, 135:975-982.
22. Soler J.J., Sánchez L., Román P., Martínez M.A., Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med 2004, 98:318-329.
23. Quint J.K., Baghai-Ravary R., Donaldson G.C., Wedzicha J.A. Relationship between depression and exacerbations in COPD. Eur Respir J 2008, 32:53-60.
24. Decramer M., Gosselink R., Troosters T., Verschueren M., Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997, 10:417-423.
25. Terada K., Muro S., Sato S., Ohara T., Haruna A., Marumo S., et al. Impact of gastroesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008, 63:951-955.
26. Takabatake N., Shibata Y., Abe S., Wada T., Machiya J.I., Igarashi A., et al. A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:875-885.
27. Yang I.A., Seeney S.L., Wolter J.M., Anders E.M., McCormack J.G., Tunnicliffe A.M., et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes and Immunity 2003, 4:269-274.
28. Foreman M.G., DeMeo D.L., Hersh C.P., Carey V.J., Fan V.S., Reilly J.J., et al. Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J 2008, 32:938-944.
29. Langsetmo L., Platt R.W., Ernst P., Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008, 177:396-401.
30. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
31. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?. Eur Respir J 2002, 20:9s-19s.
32. Donaldson G.C., Wedzicha J.A. COPD exacerbations. 1: epidemiology. Thorax 2006, 61:164-168.
33. Perera W.R., Hurst J.R., Wilkinson T.M.A., Sapsford R.J., Müllerova H., Donaldson G.C., et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534.
34. Kessler R., Stähl E., Vogelmeir C., Haughmey J., Trudeau E., Löfdahl C.-G., et al. Patient undestainding, detection, and experience of COPD exacerbations. An observational, interview-based study. Chest 2006, 130:133-142.
35. Seemungal T.A.R., Donaldson G.C., Bhowmik A., Jeffries D.J., Wedzicha J.A. Time course and recovery of exacerbations in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
36. Spencer S., Jones P.W. GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003, 58:589-593.
37. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with palcebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007, 146:545-555.
38. Aaron S.D., Fergusson D., Marks G.B., Suissa S., Vandemheen K.L., Doucette S., et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008, 63:122-128.
39. Hurst J.R., Donaldson G.C., Quint J.K., Goldring J.J.P., Baghai Ravary R., Wedzicha J. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:369-374.
40. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
41. Abroug F., Quanes-Besbes L., Nciri N., Sellami N., Addad F., Ben Hamda K., et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease. Diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006, 174:990-996.
42. Tille-Leblond I., Marquette C.H., Pérez T., Scherpereel A., Zanetti C., Tonnel A.B., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006, 144:390-396.
43. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
44. Paggiaro P.L., Dahle R., Bakran I., Frith L., Hollingwoth K., Efthimiou J. Multicentre randomised in patients with moderate to severe chronic obstructive pulmonary diseae: the ISOLDE trial. BMJ 2000, 20:1297-1303.
45. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomised placebo-controlled trials. Am J Med 2002, 113:59-65.
46. Tsoumakidou M., Siafakas N.M. Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations. Respiratory Research 2006, 7:80.
47. Hurst J.R., Donaldson G.C., Perera W.R., Wilkinson T.M., Bilello J.A., Hagan G.W., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
48. Rodríguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S.
49. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: Analysis by diary cards. Chest 2008, 133:34-41.
50. Xu W., Collet J.P., Shapiro S., Lin Y., Yang T., Wang C., et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010, 35:1022-1030.
51. Leidy NK, Wilcox T, Jones PW, Roberts L, Powers JH, Sethi S; the EXACT-PRO Study Group. Standardizing measurement of COPD exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2010. En prensa.
52. O'Donnell D.E., Parker C.M. COPD exacerbations. Pathophysiology. Thorax 2006, 61:354-361.
53. Donaldson G.C., Seemungal T.A.R., Patel I.S., Lloyd-Owen S.S., Bhowmik A., Wilkinson T.M.A., et al. Airway and systemic inflammation and decline in lung function, in chronic obstructive pulmonary disease. Chest 2005, 128:1995-2004.
54. Groenewegen K.H., Dentener M.A., Wouters E.F.M. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med 2007, 101:2409-2415.
55. Miravitlles M., Anzueto A., Legnani D., Forstmeier L., Fargel M. Patient's perception of exacerbation of COPD - the PERCEIVE study. Respir Med 2007, 101:453-460.
56. Kessler R., Stähl E., Vogelmeir C., Haughmey J., Trudeau E., Löfdahl C.-G., et al. Patient undestainding, detection, and experience of COPD exacerbations. An observational, interview-based study. Chest 2006, 130:133-142.
57. Miravitlles M., Ferrer M., Pont A., Zalacain R., Álvarez-Sala J.L., Masa F., et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004, 59:387-395.
58. Hurst J.R., Perera W., Wilkinson T.M., Donaldson G.C., Wedzicha J.A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:71-78.
59. Donaldson G.C., Hurst J.R., Smith C.J., Hubbar R.B., Wedzicha J.A. Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest 2010, 137:1091-1097.
60. Brekke P.H., Olmland T., Holmedadl S.H., Smith P., Soyseth V. Troponin T elevation and long-term mortality afther chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008, 31:563-570.
61. Brekke P.H., Omland T., Holmedal S.H., Smith P., Soyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. BMC Pulm Med 2009, 9:35.
62. Laukides S., Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 1996, 63:170-173.
63. Antonelli R., Fuso L., De Rosa M., Rapiti E., Nardecchia B., Pistelli R. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800.
64. Wood-Baker R.R., Gibson P.G., Hannay M., Walters E.H., Walters J.A. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, 1. CD001288.
65. Baker E.H., Janaway C.H., Philips B.J., Brennan A.L., Baines D.L., Wood D.M., et al. Hyperglycaemia is associated with poor outcomes in patient admited to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006, 61:284-289.
66. Marquis K., Maltais F., Duguay V., Bezeau A.M., Leblanc J., Jobin J., et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Cardipulm Rehabil 2005, 25:226-232.
67. Watz H., Waschki B., Kirsten A., Müller K.C., Krestschmar G., Meyer T., et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009, 136:1039-1046.
68. Lam K.B., Jordan R.E., Jiang C.Q., Thomas G.N., Miller M.R., Zhang W.S., et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010, 35:317-323.
69. Küpeli E., Ulubay G., Ulasli S.S., Sahin T., Erayman Z., Gürsoy A. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocr 2010, 38:76-82.
70. Girón R., Matesanz C., García-Río F., De Santiago E., Macha A., Rodríguez-Salvanés F., et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab 2009, 54:52-58.
71. Hopkinson N.S., Tennant R.C., Dayer M.J., Swallow E.B., Hansel T.T., Moxham J., et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Resp Res 2007, 8:25.
72. Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:358-364.
73. Makris D., Moschandreas J., Damianaki A., Ntaoukakis E., Siafakas N.M., Milic Emili J., et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007, 101:1305-1312.
74. Alfageme I., Reyes N., Merino M., Reina A., Gallego J., Lima J., et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Respir Dis 2010, 7:135-145.
75. Jones R.C., Donaldson G.C., Chavannes N.H., Kida K., Dickson-Spillmann M., Harding S., et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med 2009, 180:1189-1195.
76. Zvezdin B., Milutinov S., Kojicic M., Hadnadjev M., Hromis S., Markovic M., et al. A postmorten analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009, 136:329-330.